Bowtie Announces New Headquarters – “Bowtie Life Insurance Tower”

Bowtie, Hong Kong's first virtual insurer[1], announces the strategic relocation of its headquarters to 68 Johnston Road, Wan Chai. Effective 1 February 2026, the building will be officially renamed “Bowtie Life Insurance Tower” (“Bowtie Tower”). Located in a prime and highly visible district, this milestone marks Bowtie's growth from a home-grown startup into Hong Kong's […]

Smart Energy in Action: JA Solar’s first BESS for C&I in Sicily, Italy

JA Solar, a global leader in photovoltaic products and integrated energy solutions, announced the successful commissioning of a solar-plus-storage microgrid at a modern C&I facility in Sicily. This project represents a practical implementation of JA Solar's “PV+Storage+X” model – a flexible approach that combines solar generation and battery storage with specific industry applications (“X”) to

Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic

(SWX:BSLN.SW),(Boerse Stuttgart – Freiverkehr:BSLN),(Boerse Berlin – Freiverkehr:BSLN),(Boerse Frankfurt – Freiverkehr:BSLN),(Boerse Muenchen – Freiverkehr:BSLN), Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with Phare Bio Inc., Boston (USA), a biotech social venture

Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic

Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic GlobeNewswire December 11, 2025 Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

(Copenhagen:ZEAL), Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030 Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health GlobeNewswire December 11, 2025 Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline

HIVE Digital Technologies Enters Colombia's Deep Andean Capital Markets With Colombia Listing, Advancing Its Role as Latin America's Emerging Leader in Green AI and Bitcoin Infrastructure

San Antonio, Texas–(Newsfile Corp. – December 11, 2025) – HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (BVC: HIVECO) (the “Company” or “HIVE”), a diversified multinational digital infrastructure company, is expanding its Latin American capital-markets presence with a new listing on the Colombian Stock Exchange—one of the region’s deepest, broadest, and most institutionally

OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

— Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases — OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30

BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update

(BX Swiss AG:BIOV.SW), Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) — BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027 Significant value inflection points achieved

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

(Paris:SAN), Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year Cablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National

Scroll to Top